August 2, 2021


Guselkumab Self-Injector for Plaque Psoriasis Gets FDA Approval
Jennifer Barrett, Associate Editor
Guselkumab (Tremfya, Janssen) is a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis.
FDA Approves Subcutaneous Herceptin Combo for Breast Cancer
Jennifer Barrett, Associate Editor
Trastuzumab and hyaluronidase-oysk subcutaneous injection approved for certain patients with HER2-positive early and metastatic breast cancer.
Adverse Effects Underreported in Many Health Reviews
Jennifer Barrett, Associate Editor
Potential adverse effects from health interventions, such as a drug reaction or an effect of a procedure, were not fully reported in more than one-third of published health study reviews.
Cablivi Gets FDA Approval for Rare Blood Clotting Disorder
Jennifer Barrett, Associate Editor
Caplacizumab-yhdp treats adults with acquired thrombotic thrombocytopenic purpura, a rare and life-threatening blood clotting autoimmune disorder.  
FDA Expands Alimta Label With Keytruda for Front Line Treatment of Non-Small Cell Lung Cancer
Jennifer Barrett, Associate Editor
Pemetrexed plus pembrolizumab is indicated for use along with platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.
About the Specialty Pharmacy Times Industry Guide

The Specialty Pharmacy Times Industry Guide includes comprehensive editorial content relative to all specialty pharmacy stakeholders. Content includes information relative to market trends, commercialization, distribution, order to cash, HUB Services, managed care strategies and DIR fees. The guide also includes profiles, and a complete list of stakeholders along the patient journey: specialty pharmacies, wholesaler distributors, manufacturers, support services, group purchasing, and trade associations.

Sign Up for the Industry Guide Newsletter

Copyright © 2006-2018 Pharmacy & Healthcare Communications, LLC
All Rights Reserved

About Us   Privacy